General Updates

05 September 2026 To To National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex, 25th floor, P. J. Towers, Bandra (E), Mumbai – 400 051 Dalal Street, Mumbai – 400 001 Scrip Symbol: COHANCE Scrip Code – 543064 Dear Sir/Madam, Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Completion of USFDA Inspection Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we inform you that the United States Food and Drug Administration (USFDA) inspected the Company’s formulation (FDF) plant located at Shamshabad, Telangana, from 27 August to 4 September 2026. The inspection concluded with the issuance of a Form FDA 483 containing four observations. The Company has initiated appropriate corrective and preventive actions (CAPA) and will submit its response within the stipulated timeline. The Company remains committed to quality and regulatory compliance. This is for your information and record. Thank you. Yours faithfully, For Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Sisir K Mishra Company Secretary and Compliance Officer